BofA and TD Cowen Cut Marvell to Neutral After $115 Billion Lumentum Deal

BofA cut Marvell Technology (NASDAQ: MRVL) to Neutral from Buy and slashed its price target from $400 to $225, one of two downgrades triggered by the company's agreement to acquire Lumentum in an all-stock deal valued at roughly $115 billion including debt. TD Cowen moved the same direction, dropping the stock to Hold from Buy and cutting its target from $350 to $175. Marvell shares fell about 13% on the announcement.

BofA analyst Vivek Arya led the bearish turn. TD Cowen followed to the sidelines. The market's reaction was immediate and blunt, with the 13% share decline signaling that investors are already discounting execution risk, dilution, and the possibility that Marvell is overpaying for optical exposure at a moment when AI infrastructure valuations are stretched.

Why combine chips and optics?

The strategic logic behind the deal is straightforward. Marvell designs the chips and networking gear that move data inside AI data centers. Lumentum makes the optical components that carry that data as light. Marrying the two would hand Marvell a broader position in the optical connectivity layer of AI infrastructure, an area that could grow more critical as AI clusters scale up and data movement becomes the bigger bottleneck.

In that reading, the acquisition lets Marvell capture a larger share of AI-related spending instead of staying concentrated in its existing chip and networking footprint. More of the AI budget, more of the stack.

What does the all-stock structure cost shareholders?

The financing sits at the center of the skepticism. Because Marvell is paying with its own shares, current shareholders will own a smaller slice of a larger company. That dilution matters most while the market is still trying to value the combined business before anyone has shown how the two product lines actually fit together.

The skeptics' questions predate the announcement. Before the Lumentum news broke, the few analysts without a Buy rating on Marvell were already focused on valuation, execution risk, and the durability of the company's AI growth outlook. The deal didn't create that debate. It sharpened it.

Is Wall Street unanimous?

No, and the split is instructive. UBS reiterated its Buy rating and $350 price target on November 3, signaling that at least one major firm still sees the combination as strategically compelling. Cantor Fitzgerald stayed at Neutral but lowered its target to $225.

The divide comes down to a single trade-off: whether the optical business gives Marvell a meaningfully bigger share of AI spending, or whether the deal adds integration risk, complicates the product roadmap, and dilutes existing holders before any benefits show up.

Can the product lines actually mesh?

Investors will watch how the two companies combine their portfolios. Marvell's strengths in data-center chips and networking gear must mesh with Lumentum's optical components in a way that produces real cross-selling or bundled offerings, rather than simply a larger and more complex company. The integration question carries extra weight because the bear case was already circling Marvell weeks before this deal surfaced.

The bull case says optics expand Marvell's AI opportunity. The bear case says dilution and integration risk arrive long before the payoff is proven.

What happens next?

With targets now ranging from $175 at TD Cowen to $350 at UBS, the spread itself tells the story: the Street cannot yet agree on what a diluted, optics-heavy Marvell is worth. The next test will be whether the combined roadmap demonstrates bundled chip-plus-optics offerings, and whether execution can outrun the dilution math before investors lose patience.